Author + information
- Sining Hu,
- Haibo Jia,
- Jingbo Hou,
- Xing Lei,
- JinWei Tian,
- Koji Kato,
- Taishi Yonetsu,
- Rocco Vergallo,
- Farhad Abtahian,
- zhigang han,
- Lingbo Meng,
- Huai Yu,
- Shaosong Zhang,
- Bo Yu and
- Ik-Kyung Jang
Patients with diabetes mellitus (DM) have higher mortality and morbidity despite intense lipid lowering therapy. The underlying pathophysiology is not well understood.
We compared the changes in plaque characteristics in response to statin therapy between DM and non-DM patients using optical coherence tomography (OCT)
Fibrous cap thickness (FCT) in non-culprit lipid plaque was measured at baseline, 6 months, and 12 months in 22 DM and 20 non-DM patients. Blood samples for lipid and hs-CRP were drawn at each time point.
Fibrous cap became thicker with lipid lowering therapy in both DM patients (from 65.2 ± 15.6 µm at baseline to 81.1 ± 22.3 µm at 6 months to 101.4 ± 30.6 µm at 12 months, all p < 0.01) and Non-DM patients (from 58.9 ± 14.0 µm at baseline to 89.1 ± 25.1 µm at 6 months to 118 ± 44.5 µm at 12 months, all p < 0.01). However, the percent change in FCT in non-DM patient was significantly greater than in DM patient both at 6-months and 12-months (Figure). The change in low density lipoprotein cholesterol level and the change in hs-CRP were both similar between the DM patients and non-DM subjects at 6 months, and 12 months.
Despite equivalent improvement of laboratory values, plaque stabilization was significantly attenuated in DM patients.
Poster Sessions, Expo North
Monday, March 11, 2013, 9:45 a.m.-10:30 a.m.
Session Title: ACS Therapy: Basic and Translational
Abstract Category: 3. Acute Coronary Syndromes: Therapy
Presentation Number: 1301-185
- 2013 American College of Cardiology Foundation